Galecto Biotech

A Correction to this article was published on 10 September 2013

This article has been updated

By targeting a sugar-binding protein, a Swedish startup hopes to provide new lung fibrosis treatments.

This is a preview of subscription content, access via your institution

Access options

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

30 August 2013
In the version of the article entitled “Galecto Biotech” (Nat. Biotechnol. 31, 481, 2013) originally published, in paragraph 2, “Galectin-3” was said to be “like,” but is “unlike other lectins.” The photo caption should have included Hans Schambye, also a co-founder; and Tariq Sethi's first name was misspelled as Tarik. At the end of the article, Raghu Kalluri's name was misspelled as Khalluri. The errors have been corrected in the HTML and PDF versions of the article.

Authors

Garber, K. Galecto Biotech. Nat Biotechnol 31, 481 (2013). https://doi.org/10.1038/nbt0613-481

Quick links